Physician profile
Naresh Ganesh
NPI 1558468942
$1,198.59
in general payments reported to CMS, 2019-2025
14 companies · $77.26 in 2025
The $77.26 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2021: $28.43 · 2022: $85.86 · 2023: $382 · 2024: $252 · 2025: $77.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.35 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $402.24 | 2019-2024 | Recarbrio, Delstrigo, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.19 | 2019 | |
| Sk Life Science, INC. | $171.02 | 2023 | Xcopri |
| Bayer Healthcare Pharmaceuticals INC. | $117.95 | 2023 | |
| Abbott Laboratories | $75.63 | 2021-2022 | |
| Abbvie INC. | $45.99 | 2024-2025 | |
| Melinta Therapeutics, LLC | $44.32 | 2024 | Rezzayo, Kimyrsa |
| Smith+Nephew, INC. | $34.18 | 2024-2025 | Collagenase Santyl, Regranex |
| Novartis Pharmaceuticals Corporation | $31.24 | 2022-2023 | |
| Lilly USA, LLC | $26.12 | 2024 | |
| Pfizer INC. | $22.72 | 2025 | |
| Philips North America LLC | $20.42 | 2022 | |
| Shionogi INC | $20.18 | 2025 | Fetroja |
| Viiv Healthcare Company | $13.39 | 2024 | Dovato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Ganesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.